SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CME Telemetrix
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: chrisco who wrote (7)1/26/1998 3:51:00 PM
From: stephen  Read Replies (1) of 12
 
That in fact is true. From what I can ascertain from the company
as well as Medisense (Abbott's subsidiary), the pull out in funding
had nothing to do with CME's science and technology. It was more
of a general cutback on third party R and D projects. However,
it obviously impacts short-term on CME's credibility. I have heard
from several sources that they are looking at other joint venture
partners, and are expected to do something in the next few months.
Their investment relations department also tell me that the clinicals
are going well and that their timeline to FDA is on track. Also, they
have enough cash to last for quite a while, so funding is not a
concern. But I do feel they need another joint venture partner to
again establish strong credibility in the biotechnology industry.
Anyone else have some thoughts?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News